Gene therapy, CRISPR, synthetic biology, and emerging platforms—what's real, what's hype, and what translates.
Celcuity’s intravenously infused Revtorpyk has gained FDA approval for advanced breast cancer, representing the first in a novel class targeting a key cancer-associated pathway.
Celcuity’s intravenously infused Revtorpyk has gained FDA approval for advanced breast cancer, representing the first in a novel class targeting a key cancer-associated pathway.
READ MORE
A recent study provides unprecedented insights into how Epstein-Barr virus (EBV) infection can provoke the immune responses seen in multiple sclerosis (MS). Researchers are unraveling the complex interplay between viral triggers and autoimmune pathology.
Spero Therapeutics and Innovent Biologics have entered a deal worth up to $1.1 billion for development rights to SP001, targeting IgG4-related disease with a novel anti-CD40L antibody.
GSK’s immunotherapy Jemperli has achieved a pivotal milestone in a Phase 2 study targeting a rare form of rectal cancer, potentially setting a new paradigm for regulatory approval and treatment pathways in oncology.
Recent conversations on obesity genetics remain overly focused on two variants, overshadowing the sophisticated genetic landscape that drives risk—and missing crucial insight for tailored interventions.
At this year’s Alzheimer’s Association International Conference, new research highlighting tau pathology and advances in crossing the blood-brain barrier captured the biomedical spotlight.
The ARPA-H agency is investing $160 million to accelerate development of tailored gene editing therapies, signaling a new era for rare disease treatment innovation and translational research in genomic medicine.
A Connecticut startup is pushing for a paradigm shift in drug testing, championing whole-organ experiments as the frontier beyond organoids and organ-on-a-chip models. With the FDA shifting away from animal models, the landscape of preclinical research is poised for transformation.
Veradermics has become a post-IPO sensation, posting a remarkable 656% stock climb as it leverages the consumer momentum behind obesity treatments. The intersection of hair loss and metabolic wellness is shaping a new biotech frontier.
Celea Therapeutics, a PureTech Health spinout, has acquired $180 million in funding to advance its idiopathic pulmonary fibrosis candidate, deupirfenidone, into a pivotal Phase 3 trial. The oral small molecule will be evaluated head-to-head against a standard-of-care IPF drug.
The biotech sector has sustained a robust rally since April 2025, accelerating further into mid-2026. Analysts are now examining the driving forces, sustainability, and the broader implications of this sector-wide boom.
